Thomas  Catinazzo net worth and biography

Thomas Catinazzo Biography and Net Worth

Tom Catinazzo brings to Relay more than 12 years of extensive experience in the biotechnology field. Prior to Relay, he was vice president of financial planning and analysis at Foundation Medicine, where he was responsible for overseeing all aspects business planning functions. Previously, Tom worked at Aileron Therapeutics, as well as Genzyme Corporation, supporting both the renal and personalized genetic health division.

Tom holds a B.S. from Boston College.

What is Thomas Catinazzo's net worth?

The estimated net worth of Thomas Catinazzo is at least $2.09 million as of July 29th, 2024. Mr. Catinazzo owns 319,650 shares of Relay Therapeutics stock worth more than $2,087,315 as of October 6th. This net worth approximation does not reflect any other assets that Mr. Catinazzo may own. Additionally, Mr. Catinazzo receives an annual salary of $663,990.00 as SVP at Relay Therapeutics. Learn More about Thomas Catinazzo's net worth.

How old is Thomas Catinazzo?

Mr. Catinazzo is currently 47 years old. There are 5 older executives and no younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics is Dr. Mark Murcko Ph.D., Co-Founder & Director, who is 64 years old. Learn More on Thomas Catinazzo's age.

What is Thomas Catinazzo's salary?

As the SVP of Relay Therapeutics, Inc., Mr. Catinazzo earns $663,990.00 per year. There are 2 executives that earn more than Mr. Catinazzo. The highest earning executive at Relay Therapeutics is Dr. Donald A. Bergstrom M.D., Ph.D., President of Research & Development, who commands a salary of $1,370,000.00 per year. Learn More on Thomas Catinazzo's salary.

How do I contact Thomas Catinazzo?

The corporate mailing address for Mr. Catinazzo and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Thomas Catinazzo's contact information.

Has Thomas Catinazzo been buying or selling shares of Relay Therapeutics?

Thomas Catinazzo has not been actively trading shares of Relay Therapeutics during the last ninety days. Most recently, Thomas Catinazzo sold 10,780 shares of the business's stock in a transaction on Monday, July 29th. The shares were sold at an average price of $8.56, for a transaction totalling $92,276.80. Following the completion of the sale, the chief financial officer now directly owns 319,650 shares of the company's stock, valued at $2,736,204. Learn More on Thomas Catinazzo's trading history.

Who are Relay Therapeutics' active insiders?

Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), and Andy Porter (Insider). Learn More on Relay Therapeutics' active insiders.

Are insiders buying or selling shares of Relay Therapeutics?

In the last twelve months, insiders at the sold shares 18 times. They sold a total of 136,450 shares worth more than $1,076,195.29. The most recent insider tranaction occured on July, 31st when insider Peter Rahmer sold 13,708 shares worth more than $112,268.52. Insiders at Relay Therapeutics own 4.3% of the company. Learn More about insider trades at Relay Therapeutics.

Information on this page was last updated on 7/31/2024.

Thomas Catinazzo Insider Trading History at Relay Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/29/2024Sell10,780$8.56$92,276.80319,650View SEC Filing Icon  
6/27/2024Sell9,373$6.24$58,487.52330,430View SEC Filing Icon  
4/29/2024Sell1,695$6.38$10,814.10339,803View SEC Filing Icon  
3/27/2024Sell348$7.70$2,679.60341,498View SEC Filing Icon  
1/29/2024Sell2,005$9.64$19,328.20341,846View SEC Filing Icon  
12/27/2023Sell294$11.51$3,383.94143,851View SEC Filing Icon  
10/30/2023Sell1,697$6.03$10,232.91144,145View SEC Filing Icon  
9/27/2023Sell294$8.38$2,463.72145,842View SEC Filing Icon  
7/28/2023Sell1,693$11.80$19,977.40146,136View SEC Filing Icon  
6/27/2023Sell294$12.12$3,563.28147,829View SEC Filing Icon  
4/28/2023Sell863$11.16$9,631.08149,272View SEC Filing Icon  
3/27/2023Sell347$15.36$5,329.92150,135View SEC Filing Icon  
1/30/2023Sell864$21.56$18,627.84150,482View SEC Filing Icon  
12/27/2022Sell445$14.49$6,448.0550,231View SEC Filing Icon  
10/28/2022Sell1,099$21.54$23,672.4650,676View SEC Filing Icon  
9/27/2022Sell443$22.73$10,069.3951,775View SEC Filing Icon  
9/8/2022Sell26,257$30.00$787,710.0052,218View SEC Filing Icon  
7/28/2022Sell734$21.26$15,604.8452,218View SEC Filing Icon  
6/27/2022Sell300$20.31$6,093.0052,952View SEC Filing Icon  
4/28/2022Sell725$25.57$18,538.2553,252View SEC Filing Icon  
3/29/2022Sell282$29.87$8,423.34View SEC Filing Icon  
3/24/2022Sell13,286$30.00$398,580.00View SEC Filing Icon  
12/27/2021Sell295$33.10$9,764.50View SEC Filing Icon  
11/15/2021Sell22,500$35.40$796,500.00View SEC Filing Icon  
9/27/2021Sell293$36.87$10,802.91View SEC Filing Icon  
9/13/2021Sell22,500$35.00$787,500.0038,077View SEC Filing Icon  
6/7/2021Sell22,500$35.00$787,500.0038,370View SEC Filing Icon  
See Full Table

Thomas Catinazzo Buying and Selling Activity at Relay Therapeutics

This chart shows Thomas Catinazzo's buying and selling at Relay Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Relay Therapeutics Company Overview

Relay Therapeutics logo
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.53
Low: $6.38
High: $6.63

50 Day Range

MA: $7.21
Low: $6.24
High: $9.51

2 Week Range

Now: $6.53
Low: $5.70
High: $12.14

Volume

1,262,163 shs

Average Volume

3,793,273 shs

Market Capitalization

$874.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64